EGFR and non-small cell lung carcinoma: Osimertinib is now an FDA-approved drug for treating patients with NSCLC that has become resistant to the first-generation EGFR-TKIs through the T790 M mutation and for EGFR mutation-positive advanced NSCLC as a first-line treatment.